Aptose Biosciences Inc. (TSE:APS – Get Free Report) (NASDAQ:APTO)’s stock price hit a new 52-week low on Thursday . The company traded as low as C$0.39 and last traded at C$0.36, with a volume of 34846 shares trading hands. The stock had previously closed at C$0.38.
Aptose Biosciences Stock Down 9.3 %
The company has a debt-to-equity ratio of 670.80, a quick ratio of 5.41 and a current ratio of 0.80. The firm has a market capitalization of C$6.16 million, a price-to-earnings ratio of -0.07 and a beta of 1.36. The business’s 50-day moving average is C$0.52 and its two-hundred day moving average is C$0.85.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Stories
- Five stocks we like better than Aptose Biosciences
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Why Palo Alto Networks’ Multi-Year Uptrend Is Far From Over
- Why Are Stock Sectors Important to Successful Investing?
- 3 Rock-Solid Buying Opportunities in the Market Right Now
- Trading Stocks: RSI and Why it’s Useful
- TJX Companies Stock Poised to Hit a New High This Year
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
